MedImmune, a Greater Washington biotechnology cornerstone, is racing to fill the pipeline for parent AstraZeneca (NYSE: AZN) with drug candidates that harness the power of the immune system, even against cancer. And it’s using precision medicine to do it.
{iframe}http://www.bizjournals.com/washington/blog/2015/10/heres-how-medimmune-is-using-precision-medicine-to.html?ana=e_du_pap&s=article_du&ed=2015-10-21&u=wjGEy67ABoSnsLErlc5ry0j5hx3&t=1445548380{/iframe}